ACM Global appoints Asia Pacific general manager

He will initially build ACM Global team in India

ACM Global Central Laboratory has announced the newest member of its Clinical Trials team, Nandan Rao as general manager, Asia Pacific. He will be located in Mumbai, India and initially will have oversight of trials conducted with ACM Global’s partner lab in the region.

Rao will also be building the ACM Global infrastructure and team throughout Asia Pacific.

Rao was formerly general manager of SRL, the largest clinical reference laboratory network in India and Southeast Asia, where he built the firm’s clinical trials operations.

‘Since establishing its presence in India in 2006, ACM has become a global leader in the central lab arena,’ said Elena Logan, VP of Clinical Trials at ACM Global Central Lab.

‘Nandan’s expertise in building a central lab group in this region will be of significant value to our organisation as we continue to expand ACM Global wholly owned locations.’

You may also like

Regulatory

ACM Global relocates European hq to expanded lab facilities

Moves into a new, state-of-the-art facility in York, UK
Regulatory

ACM Global Central Laboratory establishes Mumbai subsidiary

Operational facility is dedicated to managing clinical trials testing in India and study support in Asia Pacific
Packaging

SGD Pharma acquires Alphial Srl in a strategic step forward

SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy
Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Finance

Piramal and NewAmsterdam Pharma invest in a dedicated suite to enhance oral solid dosage production

The multimillion-dollar investment provides NewAmsterdam Pharma with the commercial capacity to produce a fixed-dose combination (FDC) of obicetrapib and ezetimibe to meet commercial demand
Manufacturing

Suncombe launches compact pH neutralisation systems for labs and small facilities

Expanded SUNpH range delivers compliance and performance in space-limited settings
Subscribe now